BIOMAT Database Logo BIOMAT Database Logo

[Studies on the fate of 5-fluoro-1,3-bis(tetrahydro-2-furanyl)-2,4-pyrimidinedione (FD-1), a new antitumor agent. I. Absorption, distribution, excretion and metabolism of FD-1 administered orally to rats (author's transl)]. 1978

Y Kawaguchi, and Y Nakamura, and T Sato, and S Takeda, and T Marunaka, and S Fujii

UI MeSH Term Description Entries
D008297 Male Males
D011744 Pyrimidinones Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O. Pyrimidinone,Pyrimidone,Pyrimidones
D005663 Furans Compounds with a 5-membered ring of four carbons and an oxygen. They are aromatic heterocycles. The reduced form is tetrahydrofuran. Tetrahydrofurans
D000042 Absorption The physical or physiological processes by which substances, tissue, cells, etc. take up or take in other substances or energy.
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014018 Tissue Distribution Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios. Distribution, Tissue,Distributions, Tissue,Tissue Distributions
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

Y Kawaguchi, and Y Nakamura, and T Sato, and S Takeda, and T Marunaka, and S Fujii
Review of a new antimetabolic agent, 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione (FD-1).
January 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
Y Kawaguchi, and Y Nakamura, and T Sato, and S Takeda, and T Marunaka, and S Fujii
Effects on 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione(FD-1) on the central nervous system: 1. Effects on monoamines in the brain.
October 1980, Archives internationales de pharmacodynamie et de therapie,
Y Kawaguchi, and Y Nakamura, and T Sato, and S Takeda, and T Marunaka, and S Fujii
Effects of 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione (FD 1) on the central nervous system: (2) Effects on nigro-striatal dopaminergic neurons.
July 1981, Archives internationales de pharmacodynamie et de therapie,
Y Kawaguchi, and Y Nakamura, and T Sato, and S Takeda, and T Marunaka, and S Fujii
Studies on antitumor agents, 2. Syntheses and antitumor activities of 1-(tetrahydro-2-furanyl)-5-fluorouracil and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil.
August 1978, Journal of medicinal chemistry,
Y Kawaguchi, and Y Nakamura, and T Sato, and S Takeda, and T Marunaka, and S Fujii
Studies on tetrahydrofuranyl-5-fluorouracils. 2. NMR studies of 1-(tetrahydro-2-furanyl)-, 3-(tetrahydro-2-furanyl)-, and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracils.
January 1979, Nucleic acids symposium series,
Y Kawaguchi, and Y Nakamura, and T Sato, and S Takeda, and T Marunaka, and S Fujii
Differential effects of 5-fluorouracil analogs on humoral and cell-mediated responses in mice: augmentation of delayed hypersensitivity response against picryl chloride by 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione (FD-1), a new anti-tumor drug.
November 1980, Journal of clinical & laboratory immunology,
Y Kawaguchi, and Y Nakamura, and T Sato, and S Takeda, and T Marunaka, and S Fujii
Metabolism of 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil in mice.
August 1979, Journal of the National Cancer Institute,
Y Kawaguchi, and Y Nakamura, and T Sato, and S Takeda, and T Marunaka, and S Fujii
Quantitative determination of 1,3-bis(tetrahydro-2- furanyl)-5-fluoro-2,4-pyrimidinedione and its metabolites in plasma by high-pressure liquid chromatography and gas chromatography-mass fragmentography.
September 1978, Journal of chromatography,
Y Kawaguchi, and Y Nakamura, and T Sato, and S Takeda, and T Marunaka, and S Fujii
Quantitative determination of 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione and its metabolites in visceral tissues by high-performance liquid chromatography and gas chromatography-mass fragmentography.
January 1980, Journal of chromatography,
Y Kawaguchi, and Y Nakamura, and T Sato, and S Takeda, and T Marunaka, and S Fujii
Effects of a fluorinated pyrimidinedione anti-cancer drug, 5-fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione (FT), and related compounds on nigro-striatal dopaminergic neurons in the central nervous system.
March 1985, Archives internationales de pharmacodynamie et de therapie,
Copied contents to your clipboard!